Literature DB >> 32617219

Outcome at Six Months After Primary Percutaneous Coronary Interventions Performed at a Rural Satellite Center of Sindh Province of Pakistan.

Syed F Mujtaba1, Muhammad N Khan2, Hina Sohail1, Jawaid A Sial3, Musa Karim4, Tahir Saghir3, Kiran Abbas5,6, Moiz Ahmed5,6, Nadeem Qamar3.   

Abstract

Introduction Primary percutaneous coronary intervention (PPCI) is now a well-established treatment of acute ST-elevation myocardial infarction (STEMI). For the first time in Pakistan, various off-site satellite centers are established to perform PPCI 24-hours. Our population mainly resides in the rural area with low literacy rate and poor socioeconomic conditions. The majority of the patients who are presented in the satellite center had either never received any long-term treatment plan or were non-compliant to their medication. The objective of this study was to determine the outcome of patients at six months who underwent primary PCI at a rural satellite center of Sindh, Pakistan. Methods This study was conducted at Larkana satellite center of National Institute of Cardiovascular Diseases, Karachi. Patients who underwent PPCI for STEMI from October 2017 to March 2018 were enrolled in the study. In case of death of the patient, data were obtained from the attendant of the deceased. Patients, on follow-up visits, were interrogated for post-procedure symptoms. Results A total of 271 patients were enrolled in the study. The mean age ± standard deviation of patients was 54.84 ± 10.64 years. The most common culprit artery was left anterior descending (LAD) artery with 161 (59.4%) patients, followed by right coronary artery (RCA) with 98 (36.2%) patients. Only 41 (15%) patients had a three-vessel disease, while 141 (52%) patients had single-vessel disease. On follow-up, 70 (25.8%) patients complained of chest pain grade II, 20 (7.4%) complained of shortness of breath (SOB) grade II, 44 (16.2%) complained of vertigo, and 16 (5.9%) complained of nonspecific weakness. The mortality rate of 6.3% (17) was observed after six months of PPCI. The mortality rate was found to be lower for patients with LAD disease (p = 0.036) and higher among patients with RCA as the culprit artery (p = 0.045). The mortality rate was significantly associated with the number of diseased vessels and the type of stent deployed. Conclusion Primary PCI, at a rural satellite center, has an overall positive outcome. Steps should be taken to provide free medication along with encouragement towards compliance of dual antiplatelet medication. Furthermore, the facility for subsequent procedures should be provided at the same set-up.
Copyright © 2020, Mujtaba et al.

Entities:  

Keywords:  acute myocardial infarction; angiography; culprit vessel; des; pci; percutaneous coronary intervention

Year:  2020        PMID: 32617219      PMCID: PMC7325348          DOI: 10.7759/cureus.8345

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


Introduction

The gold standard treatment for acute ST-elevation myocardial infarction (STEMI) is the primary percutaneous coronary intervention (PPCI) [1-3]. Therefore, various offsite satellite centers in rural areas in the Sindh province of Pakistan have been established. An offsite satellite center is defined as a center with no facility to perform an emergency coronary artery bypass graft (CABG). The location of these satellite centers is such that no area is outside of a two-hour travel distance away. Percutaneous coronary intervention (PCI) is performed by experienced operators as per European guidelines in these centers, round the clock [4-6]. These centers are equipped with enough procedural facilities and expertise to run as a separate entity. According to the European Society of Cardiology (ESC) and the American Heart Association (AHA) guidelines, an annual volume of at least 75 procedures at an institute performing at least 400 PCIs per year is recommended to maintain competency of a facility [7,8]. Regulation and maintenance of these satellite centers are the responsibility of the National Institute of Cardiovascular Diseases (NICVD), Karachi, which is the world’s largest PPCI center. No such facility was previously present in the rural areas of Pakistan. Majority of these areas have a low literacy rate and poor socioeconomic conditions. Our study is unique in two aspects. Firstly, the setting of the study was a twenty-four hour open facility for PPCI. Secondly, most of our population belonged to the rural area. The majority of the patients who presented to the satellite center had either never received any long-term treatment plan or were non-compliant to their medication [9]. Most of the patients belonged to a poor socioeconomic class and were not able to afford the treatment cost of subsequent procedures including CABG. Therefore, the outcome may vary as compared to the studies from the first-world countries.

Materials and methods

This study was conducted at Larkana satellite center of National Institute of Cardiovascular Diseases. Patients who underwent PPCI for STEMI from October 2017 to March 2018 were enrolled in the study. Demographic information and medical history of the participants were retrieved from the hospital records. Angiographic profile and procedural characteristics were also recorded. The researchers obtained the post-procedure outcome after six months of the PPCI from the patients during the follow-up visit. The researchers retrieved the information over a phone-call for those patients who missed their follow-up visits. Before data collection, all patients gave informed verbal consent to participate in the study. The primary outcome of interest was all-cause mortality after six months of the PPCI. The secondary outcomes were stent thrombosis, stenosis, re-infarction, stroke, or emergency CABG surgery. Patients also complained about their other symptoms like angina, dyspnea, weakness, and vertigo on the follow-up visit. A predefined Pro-forma was used to record the demographic and clinical outcomes for each patient. The data were analyzed using Statistical Package for the Social Sciences (SPSS), version 21.0 (IBM Corp., Armonk, NY). Mean ± standard deviation (SD) or percentage (frequency) was used to present continuous data while a chi-squared test was applied to assess the association between outcome, demographic, and clinical characteristics. A probability value (p-value) of less than 0.05 was considered to be statistically significant.

Results

A total of 271 patients participated in the study. Out of these, 234 (86.3%) were male and 37 (13.7%) were female. Mean age of the patients was 54.84 ± 10.64 years. Forty (14.8%) of them were under the age of 40 years, while 90 (33.2%) respondents were above the age of 60 years. We reported a strong-risk profile with diabetic, hypertensive, and obese patients. Demographic profile and baseline risk factors have been presented in Table 1.
Table 1

Demographic profile, baseline risk factors, and disease burden

CharacteristicsTotal (n = 271)
Age (years)53.94 ± 11.47
Up to 40 years40 (14.8%)
41 to 60 years141 (52.0%)
Older than 60 years90 (33.2%)
Gender
Male234 (86.3%)
Female37 (13.7%)
Risk factors
Diabetes mellitus105 (38.7%)
Hypertension177 (65.3%)
Smoking112 (41.3%)
Obesity18 (6.6%)
The most commonly localized culprit lesion was the left anterior descending (LAD) artery with 161 (59.4%), followed by the right coronary artery (RCA) for 98 (36.2%) patients. Nearly 15% (41) patients had a three-vessel disease, whereas, 52% (141) patients had a single-vessel involved. Fifteen (5.2%) patients were treated with plain old balloon angioplasty (POBA), whereas 49.1% (133) and 45.8% (124) patients were treated with drug-eluting stent (DES) and bare-metal stent (BMS), respectively. Disease burden, localization of culprit lesion, and type of stent deployed during the procedure are presented in Table 2.
Table 2

Disease burden, localization of culprit lesion, and type of stent deployed during the procedure

LAD: Left anterior descending; RCA: Right coronary artery; CX: Circumflex artery; OM branch: Obtuse marginal branch; SVD: Single-vessel disease; 2VD: Two-vessel disease; 3VD: Three-vessel disease; DES: Drug-eluting stent; BMS: Bare-metal stent; POBA: Plain old balloon angioplasty.

Culprit Artery
LAD161 (59.4%)
RCA98 (36.2%)
CX10 (3.7%)
OM branch4 (1.5%)
Diagonal1 (0.4%)
Number of Vessels Involved
SVD141 (52%)
2VD89 (32.8%)
3VD41 (15.1%)
Type of Stent Deployed
DES133 (49.1%)
BMS124 (45.8%)
POBA14 (5.2%)

Disease burden, localization of culprit lesion, and type of stent deployed during the procedure

LAD: Left anterior descending; RCA: Right coronary artery; CX: Circumflex artery; OM branch: Obtuse marginal branch; SVD: Single-vessel disease; 2VD: Two-vessel disease; 3VD: Three-vessel disease; DES: Drug-eluting stent; BMS: Bare-metal stent; POBA: Plain old balloon angioplasty. On follow-up, 70 (25.8%) complained of chest pain grade II, 20 (7.4%) complained of shortness of breath (SOB) grade II, 44 (16.2%) complained of vertigo, and 16 (5.9%) complained of nonspecific weakness. Outcomes after six months of the primary percutaneous coronary interventions (PPCI) are presented in Table 3. On analysis of outcome, no patient had a stent-related complication (in-stent restenosis), five (1.8%) underwent subsequent stage percutaneous coronary intervention (PCI), and two (0.7%) underwent coronary artery bypass grafting (CABG). Among other outcomes, three (1.1%) patients had a cerebrovascular accident (CVA), two (0.7%) had major surgeries, and five (1.8%) had other major complications. The mortality rate of 6.3% was observed after six months of the primary PCI.
Table 3

Outcomes after six months of the primary percutaneous coronary interventions (PPCI)

ACE: Angiotensin-converting enzyme

Drug Compliance
Aspirin231 (85.2%)
Clopidogrel229 (84.5%)
Beta-Blocker225 (83%)
ACE inhibitor197 (72.7%)
Statin185 (68.3%)
Symptoms
Chest pain (grade II)70 (25.8%)
Shortness of breath (grade II)20 (7.4%)
Vertigo44 (16.2%)
Nonspecific weakness16 (5.9%)
None121 (44.6%)

Outcomes after six months of the primary percutaneous coronary interventions (PPCI)

ACE: Angiotensin-converting enzyme Mortality rate after six months of the PPCI was found to be lesser for the patients with culprit LAD artery, 3.7% vs. 10%, p = 0.036, and higher among patients with RCA as culprit artery, 10.2% vs. 4%, p = 0.045. Mortality rate after six months of PPCI was found to be positively associated with the number of diseased vessels and the type of stent deployed. Mortality after six months of the PPCI by baseline characteristics is presented in Table 4.
Table 4

Mortality after six months of the primary percutaneous coronary interventions (PPCI) by baseline characteristics

LAD: Left anterior descending; RCA: Right coronary artery; SVD: Single-vessel disease; 2VD: Two-vessel disease; 3VD: Three-vessel disease; DES: Drug-eluting stent; BMS: Bare-metal stent; POBA: Plain old balloon angioplasty.

CharacteristicsBaseOutcomeP-value
Frequency ExpiredAlive
Age
Up to 40 years401 (2.5%)39 (97.5%)0.350
41 to 60 years1418 (5.7%)133 (94.3%)
More than 60 years908 (8.9%)82 (91.1%)
Gender
Male23414 (6%)220 (94%)0.620
Female373 (8.1%)34 (91.9%)
Involvement of LAD artery
Yes1616 (3.7%)155 (96.3%)0.036*
No11011 (10%)99 (90%)
Involvement of RCA
Yes9810 (10.2%)88 (89.8%)0.045*
No1737 (4%)166 (96%)
Number of Vessels Involved
SVD1414 (2.8%)137 (97.2%)0.001*
2VD895 (5.6%)84 (94.4%)
3VD418 (19.5%)33 (80.5%)
Type of Stent Deployed
DES1335 (3.8%)128 (96.2%)0.029*
BMS1249 (7.3%)115 (92.7%)
POBA143 (21.4%)11 (78.6%)

Mortality after six months of the primary percutaneous coronary interventions (PPCI) by baseline characteristics

LAD: Left anterior descending; RCA: Right coronary artery; SVD: Single-vessel disease; 2VD: Two-vessel disease; 3VD: Three-vessel disease; DES: Drug-eluting stent; BMS: Bare-metal stent; POBA: Plain old balloon angioplasty.

Discussion

Our study reported a six-month mortality rate of 6.3%. This is in accord with another report from an offsite PPCI center in the Netherlands [10]. Another study showed a higher 30-day mortality rate of 7% [11]. Another study, conducted in Cairo showed much higher mortality of 12% at six months [12]. In our population, the mortality rate was expected to be higher than the other studies because of many factors. Due to costly medication, patients who undergo percutaneous coronary intervention do not comply with dual antiplatelet therapy. Subsequent procedures of either stage PPCI or CABG were advised to patients but, only a few patients gave consent. Our patients mainly belonged to low socioeconomic status and were not well-educated. This impeded their fast recovery as they were less compliant with medication and surgical protocol. Dual antiplatelet is very important in the initial days postoperatively [13,14]. Guidelines recommend at least one year of dual antiplatelet therapy in acute coronary syndrome (ACS) patients [15]. Continuation of dual antiplatelet for at least 12 months is essential with DES implantation, otherwise, the risk of stent thrombosis and in-stent restenosis (ISR) increases [7,8,16,17]. In the present study, the compliance rate for dual antiplatelet therapy was 85% at six months of PPCI. One study has reported a compliance rate of 95% after acute myocardial infarction (AMI), which is much higher than our population [18]. Lower compliance to dual antiplatelet therapy can be due to financial constraints or due to improper counselling regarding the continuation of these drugs. Several studies have shown that low socioeconomic status and lack of awareness are the two critical factors, contributing to drug non-compliance [19,20]. Majority of our population belonged to a low socioeconomic background and were uneducated. The immediate relief from distressing symptoms following PPCI disinclines the patients to stick to their regular medications, which have no short-term effect on their symptoms. The side effects of these drugs can easily cause them to become non-compliant. Majority of these patients had been advised for the subsequent procedures either of stage PCI or CABG. However, very few of the patients underwent the recommended procedures. This could also be due to the immediate relief in symptoms following primary PCI, making them less worried about their condition. Secondly, at the time of the study, CABG was not done at this setup. The patient would have to travel about 500 kilometres away for the subsequent procedures. The low socioeconomic class usually cannot afford the transportation cost from one city to the other. Our study showed that patients with three-vessel disease had higher mortality as compared to patients with one-vessel disease. This was in accord with other studies [21-24]. In spite of being advised, the majority of these patients did not undergo any subsequent surgery. Only seven patients underwent CABG and stage percutaneous coronary intervention (PCI). This finding was similar to other studies where the prognosis was better in total revascularization rather than culprit vessel PCI only [25-27]. Our study showed that patients with a culprit artery other than the LAD artery had higher mortality. Even without any subsequent procedures, the patients involving the LAD artery remained symptom-free. We reported an increased mortality rate in patients with the right coronary artery (RCA) disease. This can be a reflection of the same trend that once RCA is stented, patients even with two- or three-vessel disease did not undergo a subsequent procedure. In contrast, one of the studies reported poorer outcomes with the involvement of the LAD artery [28]. We also reported higher mortality in patients in which isolated POBA was done. We conducted POBA mostly in the setting of a diffuse-disease, where the aim was to restore blood flow to the heart. POBA was only preferred in very critical situations. Therefore, the average mortality was high.

Conclusions

An overall good outcome was observed at six months after primary percutaneous coronary interventions (PPCI) at a rural satellite center in Pakistan. The most important factor resulting in an unsatisfactory outcome was the non-compliance of patients with the dual antiplatelet therapy or refusal to undergo a subsequent surgical procedure as per advice. The low socioeconomic status with a poor educational background was the biggest hindrance faced during the study. Another critical factor influencing the outcome was the involvement of a three-vessel disease with a noticeably higher mortality rate in comparison to patients with a one-vessel disease. Free of charge medication and proper counselling sessions should be provided to patients to guide them about the consequences of not availing the dual antiplatelet therapy or other subsequent surgical procedures. Also, a facility for subsequent procedures of either stage PCI or CABG near the satellite center should be considered to facilitate the low socioeconomic class.
  26 in total

1.  2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI).

Authors:  Stephan Windecker; Philippe Kolh; Fernando Alfonso; Jean-Philippe Collet; Jochen Cremer; Volkmar Falk; Gerasimos Filippatos; Christian Hamm; Stuart J Head; Peter Jüni; A Pieter Kappetein; Adnan Kastrati; Juhani Knuuti; Ulf Landmesser; Günther Laufer; Franz-Josef Neumann; Dimitrios J Richter; Patrick Schauerte; Miguel Sousa Uva; Giulio G Stefanini; David Paul Taggart; Lucia Torracca; Marco Valgimigli; William Wijns; Adam Witkowski
Journal:  Eur Heart J       Date:  2014-08-29       Impact factor: 29.983

2.  Early- and late-term clinical outcome and their predictors in patients with ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction.

Authors:  Hyun-Woong Park; Chang-Hwan Yoon; Si-Hyuck Kang; Dong-Ju Choi; Hyo-Soo Kim; Myeong Chan Cho; Young Jo Kim; Shung Chull Chae; Jung Han Yoon; Hyeon-Cheol Gwon; Young-Keun Ahn; Myung-Ho Jeong
Journal:  Int J Cardiol       Date:  2013-09-08       Impact factor: 4.164

3.  Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.

Authors:  John A Spertus; Richard Kettelkamp; Clifton Vance; Carole Decker; Philip G Jones; John S Rumsfeld; John C Messenger; Sanjaya Khanal; Eric D Peterson; Richard G Bach; Harlan M Krumholz; David J Cohen
Journal:  Circulation       Date:  2006-06-12       Impact factor: 29.690

4.  Late Restenosis After Both First-Generation and Second-Generation Drug-Eluting Stent Implantations Occurs in Patients With Drug-Eluting Stent Restenosis.

Authors:  Seiji Habara; Kazushige Kadota; Akimune Kuwayama; Takenobu Shimada; Masanobu Ohya; Katsuya Miura; Hidewo Amano; Shunsuke Kubo; Yusuke Hyodo; Suguru Otsuru; Takeshi Tada; Hiroyuki Tanaka; Yasushi Fuku; Tsuyoshi Goto
Journal:  Circ Cardiovasc Interv       Date:  2016-12       Impact factor: 6.546

5.  Impact of Socioeconomic Status on Clinical Outcomes in Patients With ST-Segment-Elevation Myocardial Infarction.

Authors:  Sinjini Biswas; Nick Andrianopoulos; Stephen J Duffy; Jeffrey Lefkovits; Angela Brennan; Antony Walton; William Chan; Samer Noaman; James A Shaw; Andrew Ajani; David J Clark; Melanie Freeman; Chin Hiew; Ernesto Oqueli; Christopher M Reid; Dion Stub
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2019-01

6.  Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3—PRIMULTI): an open-label, randomised controlled trial.

Authors:  Thomas Engstrøm; Henning Kelbæk; Steffen Helqvist; Dan Eik Høfsten; Lene Kløvgaard; Lene Holmvang; Erik Jørgensen; Frants Pedersen; Kari Saunamäki; Peter Clemmensen; Ole De Backer; Jan Ravkilde; Hans-Henrik Tilsted; Anton Boel Villadsen; Jens Aarøe; Svend Eggert Jensen; Bent Raungaard; Lars Køber
Journal:  Lancet       Date:  2015-08-15       Impact factor: 79.321

7.  Randomized trial of preventive angioplasty in myocardial infarction.

Authors:  David S Wald; Joan K Morris; Nicholas J Wald; Alexander J Chase; Richard J Edwards; Liam O Hughes; Colin Berry; Keith G Oldroyd
Journal:  N Engl J Med       Date:  2013-09-01       Impact factor: 91.245

8.  Clopidogrel Therapy Discontinuation Following Drug Eluting Stent Implantation in Real World Practice in Israel.

Authors:  Miry Blich; Tawfiq Zeidan Shwiri; Sirouch Petcherski; Azriel B Osherov; Haim Hammerman
Journal:  Cardiol Res       Date:  2012-03-20

9.  Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease: the CvLPRIT trial.

Authors:  Anthony H Gershlick; Jamal Nasir Khan; Damian J Kelly; John P Greenwood; Thiagarajah Sasikaran; Nick Curzen; Daniel J Blackman; Miles Dalby; Kathryn L Fairbrother; Winston Banya; Duolao Wang; Marcus Flather; Simon L Hetherington; Andrew D Kelion; Suneel Talwar; Mark Gunning; Roger Hall; Howard Swanton; Gerry P McCann
Journal:  J Am Coll Cardiol       Date:  2015-03-17       Impact factor: 24.094

Review 10.  Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Grüntzig Lecture ESC 2014.

Authors:  Robert A Byrne; Michael Joner; Adnan Kastrati
Journal:  Eur Heart J       Date:  2015-09-28       Impact factor: 29.983

View more
  2 in total

1.  Left Ventricular Functional Remodeling after Primary Percutaneous Coronary Intervention.

Authors:  Mahesh Kumar Batra; Muhammad Atif Malik; Kamran Ahmed Khan; Lajpat Rai; Rajesh Kumar; Jehangir Ali Shah; Jawaid Akbar Sial; Tahir Saghir; Naveedullah Khan; Musa Karim
Journal:  J Cardiovasc Echogr       Date:  2022-04-20

2.  Effectiveness of Cardiac Rehabilitation in Myocardial Infarction Patients After Percutaneous Coronary Intervention.

Authors:  Zaid A Shah; Qazi Muhammad Jamal; Naveed Ullah; Tufail Ahmad; Moiz Ahmed
Journal:  Cureus       Date:  2022-07-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.